Mark Elliott Boulding, Executive VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 5,084 shares at $45.34 ($229K) on 2025-01-07, disclosed to the SEC on 2025-01-10.
Scheduled sale ($229k) by Executive VP AND CLO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $45.34 | 1,543 | $70K | 30.6% |
| 2 | $45.34 | 1,543 | $70K | 30.6% |
| 3 | $44.50 | 1,998 | $89K | 38.9% |
| Total | $45.01 avg | 5,084 | $229K | 100% |
| Filing → |
| PTCT | SELL | 2026-06-22 | $823K | — | Filing → |
| PTCT | SELL | 2026-05-19 | $203K | — | Filing → |
| PTCT | SELL | 2026-05-12 | $280K | — | Filing → |